Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

Use of GLP-1s, especially semaglutide and liraglutide, may increase risk for nonarteritic anterior ischemic optic neuropathy ...

Use of GLP-1 receptor agonists is associated with a lower risk of death than use of DPP4 inhibitors in older patients with cancer and type 2 diabetes, data suggest.

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Harvard T.H. Chan School of Public Health suggests combining GLP-1 weight-loss medication with tailored nutrition and ...

As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...